New ASX share everyone's ignoring is ready to skyrocket: ana

New ASX share everyone's ignoring is ready to skyrocket: analysts


Image source: Getty Images
An ASX share that only listed a few weeks ago is being ignored by investors, even though next month’s reporting season could light a fire under it.
That’s according to Wilson Asset Management portfolio managers Matthew Haupt, Catriona Burns and Oscar Oberg, who reckon the pathology services provider has bright long-term prospects.

Australian Clinical Labs Ltd (ASX: ACL) continues to benefit from record levels of testing due to the coronavirus, which have extended further given the spread of the more infectious Delta variant,” they wrote in a memo to clients.
“The company has 86 accredited laboratories and services in approximately 90 public and private hospitals.”

Related Keywords

Australia , Australian , Matthew Haupt , Oscar Oberg , Catriona Burns , Australian Clinical Labs Ltd , Capital Limited , Research Limited , Australian Clinical Lab , Wilson Asset Management , Clinical Labs Ltd , Australian Clinical , Clinical Labs , ஆஸ்திரேலியா , ஆஸ்திரேலிய , மேத்யூ ஹோப்ட் , ஆஸ்கார் ஓபேர்க் , மூலதனம் வரையறுக்கப்பட்டவை , ஆராய்ச்சி வரையறுக்கப்பட்டவை , ஆஸ்திரேலிய மருத்துவ ஆய்வகம் , வில்சன் சொத்து மேலாண்மை , ஆஸ்திரேலிய மருத்துவ , மருத்துவ ஆய்வகங்கள் ,

© 2025 Vimarsana